Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: exercising the sector, follow the bouncing share pricing

August 31, 2018 5:46pm

As I had stated, lighten the load as the sector opened up, floated down, was back up at mid-day and closed positive of the 45 covered companies

Still with low volume

Pre-open indications: 4 HITs and 0 MISS

When is it wrong to be RIGHT in sector prognosis?

Who is speaking-up for individual investors? Your portfolio should be profiting from RMi’s analysis!

Henry’omics:

Still into yesterday’s mantra: “SELL into STRENGTH if you have a strong percentage upside in some equity – LIGHTEN the LOAD!”

Today and yesterday MANY sold some tops and “banked” some powder as September has historically been a “contentious” pricing month as Q3 ends!

Sector equities opened up dropped at the 11:30 a.m. mark flopping back positive and closed up on Friday as the US and Canada put off resolving their trade dispute.

The Dow +2.1%) and the S&P 500 (+3%) finished August up in their best performances for the month since 2014. The NASDAQ clinched its best August since 2000, ending the month up over 5.7%.

Consumer sentiment in the US rose slightly in August, beating economist expectations for a slight decline. The University of Michigan's monthly survey of consumers hit 96.2 in the final reading of August, better than the drop to 95.5 expected. <Reuters>

The Question is … are you POSITIONED for September?

Pre-open indications: 4 HITs and 0 MISS

Adverum Biotechnologies (ADVM) closed up +$0.45 – hit;

Loads were lightened:

CRISPER Therapeutics (CRSP) closed up +$3.21 ($56.67) with a day’s low of $53.50 (sold into strength) – with an aftermarket indication of -$0.67 -hit;
Editas Medicine (EDIT) closed up +$0.67 ($32.83) with a day’s low of $31.83 (sold into strength having closed at $32.07 and opened at $32.00) – hit;
Intellia Therapeutics (NTLA) closed down -$0.25 ($30.93) with a day’s low of $30.63) (sold into strength having closed at $31.18 and opened at $31.22) – hit;

From the pre-open newsletter: “last day of the month, a long holiday weekend is ahead; are investors sure they want to be that long? The list of the overbought is heavily weighted.”

I also stated, “Labor Day in the U.S. is 9/3; markets will observe regular hours on Friday to wrap up trading in August as most trading platforms will be shuttered Monday.”

Of the 45 companies covered on Friday; 17 downside equities finished in a range of -0.10% (VSTM) to -9.54% (KOOL) while the 25 upside equities oscillated from +0.19% (BOLD) to +14.51% (HSGX) with 3 flat closes (BSTG, ONVO and AGTC ).

Daily analytics and metrics:

The Dow dropped 22.10 points or -0.09% to 25,964.82,
The S&P 500 was up +0.39 points or -0.01% to 2,901.52,
The NASDAQ was up + 21.15 points or -0.26% to 8,109.54.

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 29/13 and 3 flats;
The second hour dropped negative with an A/DL of 18/24 and 3 flats;
The mid-day flipped positive with an A/DL of 30/15 and 4 flats;
The close was positive with an A/DL of 25/17 and 3 flats;

Daily volume anomaly (increased volume versus 3 month average):

FATE (621.9 K shares traded versus 3 month average of 561.8 K
HSGX (842.2 K shares traded versus 3 month average of 134.1

Four (4) key metrics:

… The greatest volume to the downside: VSTM, KOOL, BLUE, GBT and VCEL

… Upside volume was weighted to: SGMO, CRSP, MDXG, ADVM and HSGX

… Leadership ($) to the downside: BLUE (-$7.70), RGNX (-$3, 15), AXGN (-$1.75), RARE (-$1.71) and ONCE (-$0.75)

… Best moves ($) to the upside: CRSP (+$3.21), SLDB (+$2.82), ALNY (+$0.79), EDIT (+$0.76) and STML (+$0.75)

The iShares NASDAQ Biotechnology (IBB) closed:

Friday was up +0.16%
Thursday was up +0.39%
Wednesday was +1.3%%
Tuesday was up +0.49%
Monday was up +1.75%;
Last Friday was up +0.17 %

August sessions:

Friday closed POSITIVE with 17 decliners, 25 advancers and 3 flats;

Thursday closed POSITIVE with 12 decliners, 29 advancers and 4 flats;

Wednesday closed POSITIVE with 9 decliners, 33 advancers and 3 flats;

Tuesday closed POSITIVE with 15 decliners, 28 advancers and 2 flats;

Monday closed POSITIVE with 7 decliners, 35 advancers and 3 flats;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flats;

Thursday closed NEGATIVE with 26 decliners, 16 advancers and 3 flats;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed POSITIVE with 9 decliners, 36 advancers and 0 flat;

Monday closed POSITIVE with 16 decliners, 23 advancers and 6 flat;

Friday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday closed NEGATIVE with 36 decliners, 6 advancers and 3 flat;

Tuesday closed POSITIVE with 13 decliners, 28 advancers and 4 flat;

Monday closed NEGATIVE with 24 decliners, 19 advancers and 2 flat;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Wednesday closed NEGATIVE with 25 decliners, 16 advancers and 4 flat;

Tuesday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Monday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Friday closed NEGATIVE with 37 decliners, 4 advancers and 4 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday (8/1) closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.